[PDF] Top 20 Ingeniería, globalización y estado social de derecho
Has 10000 "Ingeniería, globalización y estado social de derecho" found on our website. Below are the top 20 most common "Ingeniería, globalización y estado social de derecho".
<p>Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma</p>
... in patients with BC in a Phase I ...cohorts, patients with unresectable or metastatic UC whose disease had progressed after previous platinum- based chemotherapy were enrolled, showing durable ... See full document
9
Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma
... selected patients with no randomized studies to guide ...which patients should receive the localized treatment under ...localized treatment of the pelvic primary with RC or HDRT (+/- ... See full document
9
Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis
... severe treatment-related AEs were directly linked to an early immune response within a month after the initiation of treat- ment despite the similar characteristics of study populations, with a similar median age ... See full document
80
Atezolizumab as first line treatment for selected patients with advanced or metastatic urothelial carcinoma
... and Pembrolizumab (PD-1 inhibitor) (DUOS, ...unselected patients, illustrating response rates of 20% to 30% with durable response of over two years (Balar et ...of metastatic or unresectable ... See full document
116
A phase I/II trial of fixed dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response
... anti-PD1 treatment with radiotherapy could work synergistically and raise response rates in patients with metastatic urothelial ...combination treatment will be ... See full document
8
<p>Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date</p>
... testing pembrolizumab plus lenva- tinib for first-line treatment of unresectable HCC indicated an acceptable safety profile, with an ORR of ...be treatment related. An additional five ... See full document
8
Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma
... 175 patients enrolled, 151 received at least one dose of ...58% patients, leucopoenia in 49%, and anemia in ...(5%). Patients with renal impairment had a similar safety profile, and VFL did ... See full document
10
Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy
... Abstract: Head and neck squamous cell cancer (HNSCC) is the sixth most common malignancy worldwide, and despite advances in cytotoxic, surgical and radiation techniques, outcomes are still poor in those with both locally ... See full document
5
Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.
... transitional-cell carcinoma of the bladder, renal pelvis, ureter, or urethra that was locally advanced or metastatic (T4b and/or N1-3 and/or M1); progressive disease during or after one prior platinum-based ... See full document
77
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy
... Our initial search resulted in 381 publications after de- duplication. After title and abstract review, 198 publications were excluded, leaving 84 studies for full-text analysis. Upon full-text analysis, 50 additional ... See full document
10
<p>Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations</p>
... sorafenib treatment involves upregulation of HGF secretion and c-MET ...experimental metastatic mouse models, cabozantinib reduced the number of metastatic ...674 patients at baseline and at ... See full document
13
<p>Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab</p>
... which patients bene fi t most from the combination of immunotherapy and VEGF inhibitors, and the optimal sequence of these ...trial, patients start treat- ment with induction nivolumab plus ...assessment, ... See full document
8
<p>Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US</p>
... some patients could undergo treatment for a much longer duration than the median PFS and due to asymmetry, patients cannot undergo treatment for a much shorter period than the median ...and ... See full document
9
Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
... still patients who progress or do not respond to initial treatment, which sparked an interest in combination ...recruiting patients with metastatic UC who are randomized to durvalumab in ... See full document
26
Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer
... Abstract: Metastatic urothelial carcinoma of the bladder is an aggressive malignancy with poor prognosis, reflecting a lack of effective systemic ...of patients do not respond to ... See full document
6
From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
... that pembrolizumab and atezolizumab are active in patients who are not eligible for cisplatin-based treatment ...one treatment strategy over the other may come down to clinical judgement, ... See full document
34
<p>Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States</p>
... attacks. Pembrolizumab blocks the binding of PD-L1 protein to the PD-1 receptor, thereby allowing T cells to prevent tumor cells from functioning ...the patients but also the expres- sion of PD-L1 in immune ... See full document
80
<p>Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date</p>
... and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a heterogeneous disease previously associated with poor prognosis and limited treatment options until the advent and ... See full document
8
<p>Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data</p>
... Twenty-seven patients with DLBCL, 16 with indolent NHL, and 2 with MCL received the recommended Phase 2 dose (RP2D) of ...9 patients treated with R-pola, grade 3 – 4 neutropenia and neutropenic fever ... See full document
6
Immunotherapy in Advanced Head and Neck Squamous Cell Carcinoma: A Retrospective Evaluation in Latin America
... Cell Carcinoma of the Head and Neck (SCCHN) includes neoplasms in the oral cavity, pharynx and larynx and accounts for 90% of all head and neck cancers ...of patients with locoregionally advanced SCCHN have ... See full document
10
Related subjects